Compare MRTN & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | MGTX |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1994 | 2018 |
| Metric | MRTN | MGTX |
|---|---|---|
| Price | $14.75 | $14.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.57 |
| AVG Volume (30 Days) | ★ 688.9K | 505.8K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | 0.08 | ★ 1.30 |
| Revenue | ★ $1,131,455,000.00 | $81,391,000.00 |
| Revenue This Year | $2.23 | $141.38 |
| Revenue Next Year | $8.59 | N/A |
| P/E Ratio | $185.38 | ★ $11.52 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $9.35 | $6.62 |
| 52 Week High | $18.48 | $15.35 |
| Indicator | MRTN | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 72.85 |
| Support Level | $14.39 | $7.04 |
| Resistance Level | $15.31 | $15.35 |
| Average True Range (ATR) | 0.34 | 0.63 |
| MACD | 0.05 | 0.23 |
| Stochastic Oscillator | 28.28 | 96.42 |
Marten Transport Ltd is a temperature-sensitive and dry truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. The company operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services transporting food and other consumer packaged goods.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.